Add to Calendar 3/19/2019 8:00:00 AM 3/19/2019 10:00:00 AM The Art of the Pivot: How Companies Have Successfully Made Strategic Shifts Biotech and pharma companies often face a fork in the road where they must make a strategic directional decision to ensure value creation for shareholders and in some cases viability of the product or company. Although this happens fairly frequently in large, multinational companies, it is much more noticeable in small to mid-sized organizations where head counts and pipeline are much more concentrated. These decisions may involve a change of therapeutic focus, developing a device or platform instead of a drug, dropping other product development programs in order to focus on a priority product, downsizing, etc. Our panel of experts will discuss their own experiences in the art of the pivot and how these strategic moves, made at the right time and with the right leadership can be crucial to success. MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
President & CEO
Michael Cardone leads the company’s efforts to achieve scientific and corporate milestones. His experience includes over 15 years of scientific and business management at early to mid-stage biotech companies. Prior to Eutropics, he was a scientific co-founder of Merrimack Pharmaceuticals, a Cambridge, MA based company (NASDQ trading symbol: MACK) where he worked with the starting team to develop the oncology program. Prior to this, he led a research team in the Department of Biology at MIT developing tools for small molecule drug target identification and validation. Dr. Cardone received a Ph.D. in protein trafficking from the University of California San Francisco and completed post-doctoral studies in apoptosis signaling at the Burnham Institute in La Jolla, CA